Literature DB >> 12771787

The role of gadolinium enhanced magnetic resonance imaging for children with suspected acute pyelonephritis.

Adam C Weiser1, Samuel A Amukele, John C Leonidas, Lane S Palmer.   

Abstract

PURPOSE: The diagnosis of pyelonephritis is primarily clinical. However, the history and physical findings can be confusing in children, leading to adjunctive nuclear renal cortical scintigraphic studies (99mtechnetium dimercapto-succinic acid [DMSA]) to confirm the diagnosis. Nonetheless, ambiguity occurs when differentiating between acute pyelonephritis and chronic scarring. We report our initial experience with gadolinium enhanced inversion recovery magnetic resonance imaging (MRI) to diagnose acute pyelonephritis.
MATERIALS AND METHODS: Nine patients 7 months to 18 years old (mean age 81 months) underwent MRI to confirm radiographically a clinical suspicion of acute pyelonephritis. All patients had at least 1 prior episode of clinical pyelonephritis. Data were collected to determine whether acute pyelonephritic changes could be differentiated from chronic pyelonephritis on the basis of MRI characteristics.
RESULTS: Of the 9 patients 4 were identified as having acute pyelonephritis on MRI (persistently high signal intensity after gadolinium), 2 demonstrated evidence of postpyelonephritic scar (parenchymal loss without change in signal intensity), 1 had evidence of acute pyelonephritis and chronic changes, and 2 had a completely normal examination (decreased signal intensity after gadolinium). At our institution the billable cost of MRI to the patient is $1,329, while the billable cost of 99mtechnetium DMSA is $1,459. All patients younger than 6 years required intravenous sedation for MRI, whereas 70% of those younger than 6 years require intravenous sedation for DMSA scanning at our institution. MRI provided greater anatomical detail regarding the renal architecture without radiation exposure, and allowed the unambiguous diagnosis of acute versus chronic pyelonephritis scar in a 1-time (versus often multipart for DMSA) imaging study.
CONCLUSIONS: In cases where adjunctive imaging studies are useful to make a diagnosis gadolinium enhanced inversion recovery magnetic resonance imaging allows the detection of acute pyelonephritis rapidly, cost-effectively and safely in the pediatric population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771787     DOI: 10.1097/01.ju.0000068082.91869.29

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Pediatric applications of abdominal vascular Doppler: Part II.

Authors:  Brian D Coley
Journal:  Pediatr Radiol       Date:  2004-08-05

2.  Has the time come for a successor to DMSA scintigraphy?

Authors:  Hans Jacobsson
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

Review 3.  MR urography in children.

Authors:  J Damien Grattan-Smith; Richard A Jones
Journal:  Pediatr Radiol       Date:  2006-06-22

4.  Dynamic magnetic resonance imaging in acute pyelonephritis.

Authors:  M C Martina; P P Campanino; F Caraffo; C Marcuccio; F Gunetti; L Colla; M C Cassinis; G Gandini
Journal:  Radiol Med       Date:  2009-11-09       Impact factor: 3.469

5.  Diffusion-weighted imaging and apparent diffusion coefficient values versus contrast-enhanced MR imaging in the identification and characterisation of acute pyelonephritis.

Authors:  Riccardo Faletti; Maria Carla Cassinis; Paolo Fonio; Angela Grasso; Giacomo Battisti; Laura Bergamasco; Giovanni Gandini
Journal:  Eur Radiol       Date:  2013-07-26       Impact factor: 5.315

Review 6.  Evaluation of reflux nephropathy, pyelonephritis and renal dysplasia.

Authors:  J Damien Grattan-Smith; Stephen B Little; Richard A Jones
Journal:  Pediatr Radiol       Date:  2007-12-11

7.  The clinical and imaging presentation of acute "non complicated" pyelonephritis: a new profile for an ancient disease.

Authors:  Giorgina Barbara Piccoli; Valentina Consiglio; Maria Chiara Deagostini; Melania Serra; Marilisa Biolcati; Francesca Ragni; Alberto Biglino; Agostino De Pascale; Mauro Felice Frascisco; Andrea Veltri; Francesco Porpiglia
Journal:  BMC Nephrol       Date:  2011-12-15       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.